Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 1/20 | 0.58 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.47 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.47 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.47 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28862497 | 0.98 | TEK (0.56) | TEKPFKFB3DYRK1ACLK1CLK2 | |
| SCHEMBL19259764 | 0.81 | DYRK1A (0.48) | DYRK1ACLK1CLK2HIPK1DYRK2 | |
| SCHEMBL17809818 | 0.80 | ERN1 (0.45) | TEKDYRK1AAXLMETAP2LRRK2 | |
| SCHEMBL19662770 | 0.80 | DYRK1A (0.47) | DYRK1ACLK1CLK2HIPK1DYRK2 | |
| SCHEMBL22445210 | 0.80 | FYN (0.60) | PFKFB3DYRK1ACLK1CLK2HIPK1 | |
| SCHEMBL24289812 | 0.80 | KMT2A (0.44) | TEKPFKFB3METAP2 | |
| SCHEMBL29971615 | 0.80 | KCNH2 (0.58) | DYRK1ACLK1CLK2HIPK1DYRK2 | |
| SCHEMBL30269944 | 0.80 | AURKB (0.54) | DYRK1ACLK1CLK2HIPK1DYRK2 | |
| SCHEMBL8376983 | 0.80 | KCNH2 (0.58) | DYRK1ACLK1CLK2HIPK1DYRK2 | |
| SCHEMBL29431731 | 0.80 | FYN (0.60) | PFKFB3DYRK1ACLK1CLK2HIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580621-A2 | T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS | The Broad Institute, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050312-A2 | T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS | THE BROAD INSTITUTE, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023069884-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022034587-A1 | Traf2- AND Nck-INTERACTING KINASE (TNIK) INHIBITORS AND USES THEREOF | TNIK THERAPEUTICS LTD (IL) | 2022-02-17 | — | — | WO | disclosed |
| EP-3464286-B1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| US-20210047277-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-02-18 | — | — | US | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130203747-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-8338441-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338441-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010130034-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | USP30, USP1, USP20 | TEK 4268/4885PFKFB3 4673/4885DYRK1A 3553/4885 |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | MTOR, PDPK1, PIK3CA | TEK 1795/4885PFKFB3 479/4885DYRK1A 940/4885 |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | TEK 2247/4885PFKFB3 1169/4885DYRK1A 1035/4885 |
| US-20210047277-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | TNNI3K, TNK1, TNIK | TEK 2247/4885PFKFB3 1169/4885DYRK1A 1035/4885 |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | TEK 2734/4885PFKFB3 1851/4885DYRK1A 3664/4885 |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | TEK 2093/4885PFKFB3 2343/4885DYRK1A 4880/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TEK 3782/4885PFKFB3 2438/4885DYRK1A 4870/4885 |
| US-20130203747-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | TEK 2734/4885PFKFB3 1851/4885DYRK1A 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.